ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,050 GBX | -0.87% |
|
+0.20% | +13.68% |
| 05-03 | Angle shares up on assay development deal with AstraZeneca | AN |
| 05-03 | Angle shares up on assay development deal with AstraZenaca | AN |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
151.2
USD
Average target price
164.5
USD
Spread / Average Target
+8.76%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.68% | 235B | |
| +26.08% | 681B | |
| +21.85% | 556B | |
| -4.77% | 361B | |
| +16.97% | 325B | |
| +5.69% | 285B | |
| +3.65% | 199B | |
| -11.12% | 189B | |
| -3.40% | 157B | |
| +8.08% | 149B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca : COVID-19 Vaccine Wins Emergency Use Approval In Philippines
